Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CCL18

CCL18

Basics

Aliases:
This biomarker is also known as:
  • small inducible cytokine subfamily A (Cys-Cys), member 18, pulmonary and activation-regulated,
  • C-C motif chemokine 18,
  • Macrophage inflammatory protein 4,
  • Alternative macrophage activation-associated CC chemokine 1,
  • small-inducible cytokine A18,
  • DC-CK1,
  • chemokine (C-C), dendritic,
  • AMAC-1,
  • Dendritic cell chemokine 1,
  • AMAC1,
  • SCYA18,
  • PARC,
  • Pulmonary and activation-regulated chemokine,
  • CKb7,
  • MIP-4,
  • Small-inducible cytokine A18,
  • chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated),
  • MIP4,
  • pulmonary and activation-regulated chemokine,
  • macrophage inflammatory protein 4,
  • small inducible cytokine A18,
  • dendritic cell chemokine 1,
  • CC chemokine ligand 18,
  • CC chemokine PARC,
  • DCCK1,
  • alternative macrophage activation-associated CC chemokine 1,

View in BioMuta

Description…

CCL18, also known as MIP-4, is a member of the cytokine family, a family of secreted proteins involved in immunoregulatory and inflammatory processes. CCL18 is a Cys-Cys (CC) cytokine, characterized by two adjacent cysteines. CCL18 is a chemotactic factor that attracts lymphocytes but not monocytes or granulocytes. This chemokine attracts naive T lymphocytes toward dendritic cells and activated macrophages in lymph nodes. It may play a role in both humoral and cell-mediated immunity responses.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: CCL18

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

CCL18 has been described in the literature as a potential biomarker for ovarian, bladder, breast, and colorectal cancer. CCL18 has not been identified previously in serum as a lung cancer biomarker, but it was observed up-regulated in lung cancer in the aptamer proteomic technology study (Ostroff et al, 2010).

Performance Comment

CCL18, also known as MIP-4, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.